P186 Impact of tofacitinib maintenance therapy on key Ulcerative Colitis patient-reported outcomes of fatigue, urgency, abdominal pain and sexual dysfunction using IBDQ and SF-36 individual items as proxies (original) (raw)

Inflammatory Bowel Diseases, 2020

Inflammatory Bowel Diseases

Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program

Digestive Diseases

Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes

BMC Gastroenterology, 2015

Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis

Journal of Crohn's and Colitis, 2016

Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial

2020

Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting

Bruce Salzberg MD, FACG

Inflammatory Bowel Diseases

Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries

BMC Gastroenterology, 2023

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis

William Sandborn

Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study

Fábio V. Teixeira

Crohn's & Colitis 360

P334 Impact of disease duration on tofacitinib efficacy in patients with ulcerative colitis

Journal of Crohn's and Colitis, 2020

Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program

Gosford Sawyerr

Inflammatory Bowel Diseases

P286 Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE Open

Journal of Crohn's and Colitis, 2022

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

Dahong Yu

The New England journal of medicine, 2017

Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study

Csilla Keresztes

Inflammatory Bowel Diseases

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis

Therapeutic Advances in Gastroenterology

Efficacy and Safety of Tofacitinib for Treatment of Moderate to Severe Active Ulcerative Colitis: First Report from Iran

Homayoon Vahedi

Archives of Iranian medicine, 2021

Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open

Alimentary Pharmacology & Therapeutics

Disease Activity and Health-related Quality of Life Relationships with Work Productivity in Patients with Ulcerative Colitis in OCTAVE Induction 1 and 2 and OCTAVE Sustain

Journal of Crohn's and Colitis

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

Glenn L Gordon MD

Clinical Gastroenterology and Hepatology, 2014

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

Gut, 2017

Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation

Natalie Bohm

BMJ Open Gastroenterology

Long-term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open-label, 48-week extension study

Alimentary Pharmacology & Therapeutics, 2019

Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas’ Inflammatory Bowel Disease Registry

Vipin Arora

Crohn's & Colitis 360, 2022

The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis

Martha Bayliss

Journal of Patient-Centered Research and Reviews, 2020

P781 Treatment outcome of tofacitinib dose reduction to 5 mg BID vs remaining on 10 mg BID in patients with Ulcerative Colitis who were in stable remission on 10 mg BID: Updated 30-month data from the double-blind, randomised RIVETING study

Journal of Crohn's and Colitis, 2023

P571 Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)

Jakob Begun

Journal of Crohn's and Colitis, 2018

P550 Characterisation of hospitalised patients with ulcerative colitis treated with tofacitinib in the OCTAVE clinical programme for up to 7.8 years

Journal of Crohn's and Colitis, 2023

Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis

Muna Tahir

Digestive Diseases and Sciences

Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review

Martha Bayliss

Quality of Life Research, 2017

Tofacitinib Treatment is Associated with Modest and Reversible Increases in Serum Lipids in Patients with Ulcerative Colitis

Pam Taub

Clinical Gastroenterology and Hepatology

Delayed and limited administration of the JAKinib tofacitinib mitigates chronic DSS-induced colitis

Friederike Berberich-siebelt

Frontiers in Immunology

Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Joel Kremer

Arthritis Research & Therapy, 2015

Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis

Valery Volk

Alimentary Pharmacology & Therapeutics

Further Validation of the Crohn’s and Ulcerative Colitis Ques-tionnaire-32 (CUCQ-32) to Measure the Quality of Life in Pa-tients Treated with Biologics Therapy

Professor Laith Al-Rubaiy PhD, FRCP